Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is a multicenter, prospective, cohort study designed to evaluate the clinical outcomes and characteristics of resected stage II-IIIB anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) adult patients treated with Alectinib as adjuvant therapy in China.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak płuca we wczesnym stadium (II-IIIB), potwierdzony badaniem tkanki.
- •Rak płuca z obecnością ALK.
- •Pacjenci po operacji usunięcia guza, którzy przeszli leczenie Alectinibem bez wcześniejszej chemioterapii lub innych leków na ALK.
- •Czas od pierwszej dawki leku do wzięcia udziału w badaniu nie dłuższy niż 28 dni.
✗ Disqualifies
- •Pacjenci biorący udział w innych badaniach nad leczeniem pooperacyjnym.
- •Kobiety w ciąży, karmiące piersią lub w okresie laktacji.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (44)
Affiliated Hospital of Guangdong Medical University
Zhanjiang, China
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, China
Huai He Hospital of Henan University
Kaifeng, China
Henan Provincial Chest Hospital
Zhengzhou, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, China
Peking University First Hospital
Beijing, China
Xuanwu Hospital, Capital Medical University
Beijing, China
Hunan Cancer Hospital
Changsha, China
Changzhou First People's Hospital
Changzhou, China
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
Chengdu, China
The First Affiliated Hospital, Chongqing Medical University
Chongqing, China
The Second Affiliated Hospital of Dalian Medical University
Dalian, China
Fujian Cancer Hospital
Fuzhou, China
The Third Affiliated Hospital of Sun Yat-Sen University
Guangzhou, China
The Second Affiliated Hospital, Zhejiang University
Hangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Harbin Medical University Cancer Hospital
Harbin, China
Anhui Provincial Hospital
Hefei, China
Huzhou Central Hospital
Huzhou, China
Jiangmen Central Hospital
Jiangmen, China
Shandong Provincial Hospital
Jinan, China
Lanzhou University Second Hospital
Lanzhou, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Jiangsu Cancer Hospital
Nanjing, China
Jiangsu Province Hospital
Nanjing, China
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
Nanjing, China
Affiliated Hospital of Nantong University
Nantong, China
Ningbo No.2 Hospital
Ningbo, China
Shanghai Chest Hospital
Shanghai, China
Zhongshan Hospital Fudan University
Shanghai, China
Shanghai Pulmonary Hospital
Shanghai, China
Liaoning Provincial Cancer Hospital
Shengyang, China
Cancer Hospital Chinese Academy of Medical Sciences Shenzhen Center
Shenzhen, China
Hebei Medical University Fourth Hospital
Shijiazhuang, China
Shanxi Provincial Cancer Hospital
Taiyuan, China
Taizhou Hospital of Zhejiang Province
Taizhou, China
Chest disease hospital of Tianjin City
Tianjin, China
Wuhan Union Hospital Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, China
Wuxi People's Hospital
Wuxi, China
The Second Affiliated Hospital of Xi'an Jiao Tong University
Xi'an, China
Xi'an International Medical Center Hospital
Xi'an, China
General Hospital of Ningxia Medical University
Yinchuan, China
Affiliated Hospital of Zunyi Medical University
Zunyi, China
Trial contact
Reference Study ID Number: ML45766 https://forpatients.roche.com/ No attachments to email below.
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.